Hong Kong Holds Firm on Infant Hepatitis B VaccinationAdvisory issued by Hong Kong’s Centre for Health Protection (February 2026).
Reason: US CDC rollback on universal hepatitis B vaccination at birth, influenced by vaccine scepticism.
Risks Highlighted:Rising misinformation from overseas.Parents delaying or refusing newborn vaccination.
Increased risk of mother-to-child transmission.
Long-term danger of liver cancer linked to hepatitis B.
Why This Matters for Hong Kong
Public Health Context: Since 1988, universal infant vaccination has sharply reduced hepatitis B infections and chronic liver disease.
Current Data: A 2020–22 survey found 410,000 people in Hong Kong living with hepatitis B, making it the leading cause of liver cancer.
Government Action: In December 2025, Hong Kong launched a five-year plan to fight viral hepatitis, including expanded screening (starting February 2026) and prevention programs.
Implications for Parents & CitizensMedical Guidance: Doctors stress vaccination at birth is non-negotiable.Risk of Delay: Any hesitation increases chances of lifelong infection.
Public Awareness: Campaigns will intensify to counter misinformation and reinforce trust in science.Broader Global AngleUS Policy Shift: CDC’s rollback reflects growing vaccine scepticism, but contradicts the American Academy of Paediatrics.
Hong Kong’s Position: Rejects the US move, prioritizing science-based health policy.
Regional Lesson: Other Asian nations may look to Hong Kong’s firm stance as a model for resisting misinformation.
Reference